EGFR and non-small cell lung carcinoma: These data demonstrated that the BR2-2xPPD mediated cell cycle arrest and displayed antiproliferative activity resulting in a significant (57±1%) inhibition of proliferation of NSCLC expressing wild-type EGFR, suggesting that the BR2-2xPPD peptide could be further developed as an alternative new treatment for NSCLC expressing wild-type EGFR in the future.